Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2146007 | 0.89 | CNR2 (0.32) | ALDH1A1KDM4ENPSR1TSHRMAPK1 | |
| SCHEMBL16524300 | 0.89 | LYN (0.33) | TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL16525249 | 0.88 | KDM4E (0.32) | ALDH1A1KDM4ENPSR1TSHRMAPK1 | |
| SCHEMBL2145688 | 0.87 | KDM4E (0.35) | ALDH1A1KDM4ENPSR1TSHRMAPK1 | |
| SCHEMBL3005852 | 0.85 | MEN1 (0.38) | ALDH1A1NPSR1TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL2145824 | 0.85 | HSD11B1 (0.34) | ALDH1A1KDM4ETSHRMAPK1SMN1; SMN2 | |
| SCHEMBL2145851 | 0.83 | HSD11B1 (0.31) | ALDH1A1KDM4ETSHRSMN1; SMN2P2RX7 | |
| SCHEMBL2145911 | 0.83 | KDM4E (0.31) | ALDH1A1KDM4EGAA | |
| SCHEMBL16524594 | 0.81 | ALDH1A1 (0.31) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2145726 | 0.81 | HSD11B1 (0.34) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521616-B1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS, NOVEL CARBONYLATION LIGANDS AND CATALYST SYSTEMS INCORPORATING SUCH LIGANDS | LUCITE INT UK LTD (GB) | 2017-02-08 | — | — | EP | claimed |
| US-8969560-B2 | Process for the carbonylation of ethylenically unsaturated compounds, novel carbonylation ligands and catalyst systems incorporating such ligands | LUCITE INTERNATIONAL UK LIMITED (GB) | 2015-03-03 | — | — | US | claimed |
| US-20120330016-A1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS, NOVEL CARBONYLATION LIGANDS AND CATALYST SYSTEMS INCORPORATING SUCH LIGANDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2012-12-27 | — | — | US | claimed |
| EP-2521616-A1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS, NOVEL CARBONYLATION LIGANDS AND CATALYST SYSTEMS INCORPORATING SUCH LIGANDS | Lucite International UK Limited (GB) | 2012-11-14 | — | — | EP | claimed |
| WO-2011083305-A1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS, NOVEL CARBONYLATION LIGANDS AND CATALYST SYSTEMS INCORPORATING SUCH LIGANDS | LUCITE INTERNATIONAL UK LIMITED (GB) | 2011-07-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120330016-A1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS, NOVEL CARBONYLATION LIGANDS AND CATALYST SYSTEMS INCORPORATING SUCH LIGANDS | GRB2, CDK2, PDK1 | ALDH1A1 2038/4885KDM4E 1939/4885NPSR1 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.